Erica Lorenzon
Roche Pharma AG (Germany)(DE)
Publications by Year
Research Areas
Angiogenesis and VEGF in Cancer, Glycosylation and Glycoproteins Research, Galectins and Cancer Biology, Cancer, Hypoxia, and Metabolism, Cell Adhesion Molecules Research
Most-Cited Works
- → Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy(2013)197 cited
- → Extracellular Matrix: A Matter of Life and Death(2008)165 cited
- → MULTIMERIN2 impairs tumor angiogenesis and growth by interfering with VEGF-A/VEGFR2 pathway(2011)88 cited
- → Regulation of the Extrinsic Apoptotic Pathway by the Extracellular Matrix Glycoprotein EMILIN2(2007)83 cited
- → The Extracellular Matrix Glycoprotein Elastin Microfibril Interface Located Protein 2: A Dual Role in the Tumor Microenvironment(2010)58 cited
- → An integrated approach to quantitative modelling in angiogenesis research(2015)29 cited
- → Impact of selective anti‐BMP9 treatment on tumor cells and tumor angiogenesis(2016)15 cited
- → Abstract 2319: Dual inhibition of Ang-2 and VEGF via a novel human bispecific bivalent IgG1 CrossMAb shows potent anti-angiogenic, antitumoral, and antimetastatic efficacy and leads to a reduced side effect profile compared to single therapies(2012)3 cited
- → Data from Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy(2023)1 cited
- → Supplementary Figure 2 from Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy(2023)